Cornelia Quadt

3.8k total citations · 1 hit paper
53 papers, 2.2k citations indexed

About

Cornelia Quadt is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Cornelia Quadt has authored 53 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 21 papers in Pulmonary and Respiratory Medicine and 21 papers in Oncology. Recurrent topics in Cornelia Quadt's work include PI3K/AKT/mTOR signaling in cancer (21 papers), Advanced Breast Cancer Therapies (17 papers) and Cancer Treatment and Pharmacology (14 papers). Cornelia Quadt is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (21 papers), Advanced Breast Cancer Therapies (17 papers) and Cancer Treatment and Pharmacology (14 papers). Cornelia Quadt collaborates with scholars based in Switzerland, United States and Spain. Cornelia Quadt's co-authors include Dejan Juric, Michael Rugaard Jensen, Jordi Rodón, José Baselga, Douglas Bootle, Howard A. Burris, David Demanse, Mark R. Middleton, Martin Schüler and Carlos Garcı́a-Echeverrı́a and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Cornelia Quadt

52 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cornelia Quadt Switzerland	25	1.4k	756	591	301	273	53	2.2k
Josef Brueggen Switzerland	10	1.8k 1.3×	633 0.8×	348 0.6×	230 0.8×	381 1.4×	14	2.4k
Terence O’Reilly Switzerland	24	2.0k 1.4×	1.1k 1.5×	668 1.1×	239 0.8×	421 1.5×	36	3.2k
Ben Markman Australia	24	1.3k 0.9×	1.2k 1.6×	489 0.8×	229 0.8×	329 1.2×	75	2.5k
Muralidhar Beeram United States	27	1.3k 0.9×	1.7k 2.3×	835 1.4×	182 0.6×	380 1.4×	89	3.0k
Ayana Sawai United States	9	2.7k 1.9×	1.1k 1.5×	539 0.9×	154 0.5×	335 1.2×	10	3.3k
Joan T. Garrett United States	19	1.2k 0.8×	1.1k 1.5×	392 0.7×	206 0.7×	229 0.8×	30	2.0k
Luigi Formisano Italy	25	1.1k 0.8×	1.1k 1.5×	772 1.3×	236 0.8×	494 1.8×	73	2.2k
Jeff Sosman United States	20	1.2k 0.8×	1.2k 1.6×	301 0.5×	169 0.6×	278 1.0×	38	2.2k
Danan Li United States	16	2.3k 1.6×	1.6k 2.1×	1.0k 1.7×	137 0.5×	496 1.8×	21	3.2k
Archie Tse United States	23	1.4k 1.0×	2.0k 2.6×	947 1.6×	113 0.4×	311 1.1×	59	3.3k

Countries citing papers authored by Cornelia Quadt

Since Specialization

Citations

This map shows the geographic impact of Cornelia Quadt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cornelia Quadt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cornelia Quadt more than expected).

Fields of papers citing papers by Cornelia Quadt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cornelia Quadt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cornelia Quadt. The network helps show where Cornelia Quadt may publish in the future.

Co-authorship network of co-authors of Cornelia Quadt

This figure shows the co-authorship network connecting the top 25 collaborators of Cornelia Quadt. A scholar is included among the top collaborators of Cornelia Quadt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cornelia Quadt. Cornelia Quadt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rodón, Jordi, David Demanse, Hope S. Rugo, et al.. (2024). A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Research. 26(1). 36–36. 8 indexed citations

Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations

Schjesvold, Fredrik, Andrew Spencer, Yaël C. Cohen, et al.. (2023). Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4752–4752. 3 indexed citations

Moschetta, Michele, Toshihiko Doi, Yasutoshi Kuboki, et al.. (2023). 719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors. Annals of Oncology. 34. S496–S496. 1 indexed citations

Rodón, Jordi, David Demanse, Hope S. Rugo, et al.. (2021). 96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1. Annals of Oncology. 32. S64–S64. 2 indexed citations

Juric, Dejan, Fabrice André, Filip Jankú, et al.. (2021). Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).. Journal of Clinical Oncology. 39(15_suppl). 1054–1054. 3 indexed citations

Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →

Rodón, Jordi, José Alejandro Pérez Fidalgo, Ian E. Krop, et al.. (2018). Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 82(2). 285–298. 40 indexed citations

Toyoda, Masanori, Koichiro Watanabe, Hiromi Takeuchi, et al.. (2018). A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 83(2). 289–299. 10 indexed citations

10.

Massacesi, Cristian, Emmanuelle di Tomaso, Patrick Urban, et al.. (2016). PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy. 9. 203–203. 195 indexed citations

11.

Sessa, Cristiana, Geoffrey I. Shapiro, Kapil N. Bhalla, et al.. (2013). First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(13). 3671–3680. 119 indexed citations

12.

Garon, Edward B., Richard S. Finn, Habib Hamidi, et al.. (2013). The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics. 12(6). 890–900. 56 indexed citations

13.

Wainberg, Zev A., Adrian Anghel, Amrita Desai, et al.. (2013). Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Molecular Cancer Therapeutics. 12(4). 509–519. 58 indexed citations

14.

Juric, Dejan, Jordi Rodón, Howard A. Burris, et al.. (2012). BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Research. 72. 29 indexed citations

15.

Nagengast, Wouter B., Thijs H. Oude Munnink, Hetty Timmer‐Bosscha, et al.. (2010). ⁸⁹Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. Journal of Nuclear Medicine. 51(5). 761–767. 96 indexed citations

16.

Jensen, Michael Rugaard, Susan Ide, Josef Brueggen, et al.. (2009). Abstract #5649: Pharmakokinetic/phamacodynamic relationship of the HSP90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial. Cancer Research. 69. 5649–5649. 2 indexed citations

17.

Kaiser, Martin, Britta Lamottke, Maren Mieth, et al.. (2009). Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. European Journal Of Haematology. 84(4). 337–344. 36 indexed citations

18.

Stühmer, Thorsten, Manik Chatterjee, Ruth Seggewiss, et al.. (2009). Anti‐myeloma activity of the novel 2‐aminothienopyrimidine Hsp90 inhibitor NVP‐BEP800. British Journal of Haematology. 147(3). 319–327. 14 indexed citations

19.

Schlereth, Bernd, Cornelia Quadt, Torsten Dreier, et al.. (2005). T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunology Immunotherapy. 55(5). 503–514. 77 indexed citations

20.

Quadt, Cornelia, et al.. (1989). A randomized clinical trial comparing systemic radiotherapy versus chemotherapy versus local radiotherapy in small cell lung cancer. European Journal of Cancer and Clinical Oncology. 25(6). 933–937. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact